UPCOMING SESSIONS in ET
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next Heather Landau Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
View all sessions

Tegsedi (inotersen)

Jul 04, 2018
Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis
Background: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin ( TTR) that induce…
Read more
Generic_inotersen.jpg
Tegsedi™ to be Available on the NHS for hATTR Amyloidosis
Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi(tm) (inotersen) for the treatment of stage 1…
Read more
Martha-Gulati.jpg
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis
Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…
Read more
Inotersen-Tegsedi.jpg
FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With Polyneuropathy
The US Food and Drug Administration (FDA) has approved inotersen (Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals) for the treatment of polyneuropathy (PN) in…
Read more
Morie-Gertz-Inotersen.jpg
Inotersen: An Exciting Prospect for hATTR Amyloidosis Treatment
A new hereditary ATTR (hATTR) amyloidosis treatment, inotersen, an investigational antisense drug, may not be far from a US Food and Drug Administration (FDA)…
Read more
Subscribe to